Iridex Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤2026 revenue guidance cut to $46 million-$48 million from $51 million-$53 million
- ➤Third-quarter revenue $10.2 million, down 19% year over year
- ➤Gross margin rose to 42.4% from 32.1% year over year
- ➤Net loss narrowed to $1.4 million, or $0.08 per share
- ➤Cash and equivalents fell to $3.7 million as quarterly cash use reached $1 million
Expert Statements
Patrick Mercer, President and CEO of Iridex
“On the top line, revenue came in below our expectations this quarter, driven by weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges.”
Patrick Mercer, President and CEO of Iridex
“At the same time, we continue to experience the benefits from the cost savings programs initiated when I was named CEO, including the recent relocation of our headquarters,”
Patrick Mercer, President and CEO of Iridex
“Considering the lower revenue and our investment in inventory to manage the manufacturing facility transition, cash utilization during the quarter was only $1 million and should decrease significantly in the fourth quarter with stronger sales and reversal of the inventory stocking process”
Patrick Mercer, President and CEO of Iridex
“We are now deep into a strategic review of our product lines, and as part of that work we are reprioritizing our resources toward our most profitable opportunities.”
Patrick Mercer, President and CEO of Iridex
“With this focus, we expect to enter 2027 with better margins, a lower cost base, and a business model better aligned toward cash flow generation.”
SAN JOSE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 3, 2026.
Third Quarter 2026 Financial Highlights * Generated total revenue of $10.2 million, compared to $12.5 million in the prior year period * Cyclo G6(®) product family revenue was $3.2 million, compared to $3.5 million in the prior year period * Sold approximately 11,900 Cyclo G6 probes compared to 14,900 in the prior year period * Sold 28 Cyclo G6 Glaucoma Laser Systems compared to 30 in the prior year period
Get started
Create a free account to read the full story.
